Peloton starts dosing in Phase II trial of PT2385 to treat VHL-associated kidney cancer

US-based biotechnology firm Peloton Therapeutics has started dosing patients in its Phase II clinical trial of PT2385 for the treatment of kidney cancer caused by von Hippel-Lindau (VHL) disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news